瑋俊生物科技(00660.HK)擬配發4.645億股認購股份 總籌4413萬港元
格隆匯 11 月 27日丨瑋俊生物科技(00660.HK)發佈公告,2020年11月26日,公司與認購人朱桂平先生訂立認購協議,據此,認購人於11月27日公司股份合併生效後已有條件同意認購,而公司已有條件同意配發及發行約4.645億股認購股份,認購價為每股認購股份0.095港元。
認購股份相當於公司現有已發行股本約28%及經建議配發及發行認購股份擴大的已發行股本約21.88%。認購價每股0.0095港元較股份於認購協議日期於聯交所所報的收市價每股0.01港元折讓約5%。
董事認為,認購事項是為集團業務營運籌集額外資金的機會。認購事項還將加強集團未來業務發展的資本基礎和財務狀況。發行認購股份的所得款項總額及所得款項淨額估計分別約為4413.12萬港元及4393.12萬港元。公司擬將所得款項淨額用作集團的一般營運資金及集團業務的未來發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.